Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.
|Videos|February 3, 2017
Burnout Among Neurologists
Author(s)Bobby Lazzara, MD
What factors contributed to burnout among your fellow neurologists, and what can you do to reduce your own risk?
Advertisement
What factors contributed to burnout among US neurologists in 2016?
A total of 4,127 neurologists were surveyed using validated measurements of burnout, career satisfaction, and well-being. The results were published in the journal
Greater burnout risk was associated with: hours worked/week, nights on call/week, number of outpatients seen/week, and amount of clerical work.
Meaningful work, job autonomy, effective support staff, and epilepsy sub-specialization were associated with a lower risk.
Advertisement
Related to this article
Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.
A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
Robert Bowser, PhD, Chief Scientific Officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
Topline Phase 2 ADDRESS-LC Data Show Subgroup Benefit for Bezisterim in Long COVID
3
Brain Network Changes Appear Decades Before Motor Symptoms in Huntington Disease
4
NeuroVoices: Robert Bowser, PhD, on TDP-43’s Role in ALS
5